Stockscreener 앱 받기
183.10
1.32%
-2.44
시간 외 거래:
183.10
전일 마감가:
$185.54
열려 있는:
$186.18
하루 거래량:
444.85K
Relative Volume:
0.46
시가총액:
$9.03B
수익:
$4.02B
순이익/손실:
$-142.16M
주가수익비율:
-61.94
EPS:
-2.9563
순현금흐름:
$518.49M
1주 성능:
+2.11%
1개월 성능:
+19.21%
6개월 성능:
-2.74%
1년 성능:
+78.34%
1일 변동 폭
$182.07
$190.14
1주일 범위
$175.79
$190.14
52주 변동 폭
$101.00
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
183.10 | 9.15B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
524.57 | 195.48B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.54 | 138.36B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.01 | 46.31B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.09 | 34.18B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
335.23 | 32.95B | 3.17B | 642.63M | 516.49M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Highlights Effectiveness of VCGs in Toxicology - PharmiWeb.com
Charles River Laboratories Expected to Report Q1 2026 Earnings - HarianBasis.co
What you need to know ahead of Charles River Laboratories' earnings release - MSN
Charles River gains new outperform at RBC despite NAMs related disruption - MSN
Is Cheaper Energy and Shipping Altering The Investment Case For Charles River Laboratories (CRL)? - simplywall.st
What You Need to Know Ahead of Charles River Laboratories' Earnings Release - inkl
Charles River Labs stock (US1598641074): Why Google Discover changes matter more now - AD HOC NEWS
Charles River Laboratories Experiences Evaluation Revision Amid Mixed Market Signals - Markets Mojo
Charles River Laboratories International, Inc. $CRL Shares Purchased by Assetmark Inc. - MarketBeat
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact? - TradingKey
Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Laboratories International, Inc. (NYSE:CRL) Sees Large Increase in Short Interest - MarketBeat
Why Charles River (CRL) Is Up 5.8% After Divesting Units And Refreshing Its Leadership Team - Yahoo Finance
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
Charles River gains new Outperform at RBC despite NAMs related disruption - Seeking Alpha
Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
3 Stocks with Moat Rating Changes This Month - Morningstar
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Rebound - simplywall.st
RBC Capital initiates Charles River Labs stock at Outperform - Investing.com
RBC Capital initiates Charles River Labs stock at Outperform By Investing.com - Investing.com India
Massachusetts Financial Services Co. MA Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Does Charles River’s NSG BioLabs Tie-Up Reshape the Bull Case For Charles River Laboratories (CRL)? - Sahm
Charles River Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery - insidermonkey.com
Charles River, American Heart Association Partner to Advance Cardiovascular Health Awareness - Contract Pharma
Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity - AD HOC NEWS
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Associa - PharmiWeb.com
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association - The National Law Review
Charles River Labs stock: New Asia partnership signals growth potential - AD HOC NEWS
Charles River Labs (NYSE: CRL) CFO files Form 3 reporting zero stock ownership - Stock Titan
Charles River (CRL) Added to Tactical Outperform List by Evercore ISI - GuruFocus
Charles River Laboratories Inte (CRL) Stock forecasts - Yahoo Finance UK
United States Bioanalytical Testing Services Market Size, - openPR.com
Charles River Laboratories Inte (CRL) Stock Forecasts - Yahoo! Finance Canada
Charles River Laboratories International, Inc. (CRL) stock price, news, quote and history - Yahoo Finance UK
Charles River: Downgrading Moat Rating to None and Decreasing Fair Value Estimate to $135 - Morningstar
Downgrading Charles River's Moat Rating to None as Long-Term Outlook Appears More Competitive - Morningstar
Charles River Laboratories International, Inc. (CRL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aberdeen Group plc Purchases 88,853 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.57%
0.03%
자본화:
|
볼륨(24시간):